SoylentNews is people
SoylentNews
One-shot cures for diseases are not great for business—more specifically, they’re bad for longterm profits—Goldman Sachs analysts noted in an April 10 report for biotech clients, first reported by CNBC.
The investment banks’ report, titled “The Genome Revolution,” asks clients the touchy question: “Is curing patients a sustainable business model?” The answer may be “no,” according to follow-up information provided.
[...] The potential to deliver “one shot cures” is one of the most attractive aspects of gene therapy, genetically engineered cell therapy, and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies... While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.
[...] Ars reached out to Goldman Sachs, which confirmed the content of the report but declined to comment.
(Score: 5, Insightful) by Bot on Sunday April 15 2018, @08:02AM (1 child)
They admitted big pharma reliance on treatments instead of cures.
Another field day for the tinfoil helmets.
This report, translated:
Guys, don't fund gene therapy projects that cure, fund those who treat, even better fund those who treat in tandem with chemicals. Do it the monsanto way, not the nature way.
Guy bombing a puny dictator for a bunch of chlorine deaths has his testicles handed to these guys at home, interesting.
Account abandoned.
(Score: 0) by Anonymous Coward on Sunday April 15 2018, @07:27PM
We didn't already know that?
This is a complicated industry. They use profits from things like boner pills to pay for things like antibiotics that they have to sell despite being less effective the more doses they produce, being short term and generally not having the greatest profit margins.
The industry has a lot of problems and most of them come from the fact that they have to make a profit but are allowed to ask whatever they want knowing that somebody will have to pay and that person probably isn't the one getting the treatment.